Zoetis Inc.

Companion animal products, roughly 70% of FY2025 revenue, are predominantly chronic-disease treatments and routine preventive care, generating high repeat-purchase rates at the veterinary practice level. Apoquel for atopic dermatitis and Simparica Trio as a monthly parasiticide are renewal-driven, though demand is transactional rather than contractually locked in.

Zoetis spans companion animals (~70% of FY2025 revenue) and livestock (~29%), with revenue spread across parasiticides, dermatology, vaccines, anti-infectives, and pain management in more than 100 countries. No single product family represents more than approximately 20% of consolidated revenue, though companion animal concentration adds sensitivity to a single end-market downturn.

U.S. revenue represented approximately 54% of FY2025 total ($5.1B of $9.5B), with the remaining 46% ($4.3B) spread across Australia, Brazil, Canada, China, Germany, Japan, the UK, and other markets. No single international market approaches U.S. scale, though domestic companion animal spending trends exert a disproportionate influence on consolidated results.

Zoetis carries significant fixed R&D and manufacturing infrastructure as the market leader, enabling incremental revenue in high-demand categories to flow through at above-average margins over FY2021-FY2025. The capital intensity of biologics manufacturing and sustained R&D investment caps margin expansion relative to asset-light platform models.

Companion animal therapeutics including atopic dermatitis treatments and monthly parasiticide protocols represent repeat-prescription, non-discretionary chronic care, with biologics like Cytopoint facing no generic substitutes due to manufacturing complexity. The FY2025 revenue base grew organically through macro headwinds, reflecting the defensive repeat-purchase nature of chronic animal health treatment protocols.